JANX · Janux Therapeutics, Inc.
Market Cap
$1.15B
Shares
61.14M
JANX metrics
60 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$19.70
Market cap
$1.15B
Price action
19 metricsPrice change (1W)
+1.1%
Price change (30D)
+23.3%
Price change (3M)
+37.1%
Price change (6M)
+40.6%
Price change (YTD)
+36.9%
Price change (1Y)
-16.9%
Trailing year
Price change (5Y)
-40.9%
52-week high
$34.74
52-week low
$12.18
Change from 52-week high
-45.6%
Change from 52-week low
+55.1%
Annualized volatility
73.7%
Beta
1.1
RSI (14D)
67.8
Price vs SMA 50
+16.2%
Price vs SMA 200
+20.2%
Avg volume (3M)
974,135
Relative volume
1.0
Average dollar volume
$15.15M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
61.14M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
48.1×
reciprocal yield 2.1%
P / book
1.2
reciprocal yield 80.4%
FCF yield
-3.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-12-01
Profitability
9 metricsGross margin
—
Operating margin
-598.1%
Trailing 12 months
Net margin
-427.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$143.56M
Net income (TTM)
−$102.59M
Trailing 12 months
Diluted EPS (TTM)
$-1.64
FCF margin
-174.7%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-5.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$24.00M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.7%
Year over year · more shares
Revenue CAGR (3Y)
+5.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-11.1%
Return on assets
-10.2%
Debt / equity
—
Current ratio
16.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$41.92M
Quick ratio
16.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$970.91M
Latest balance sheet
Cash & equivalents
$27.77M
Total assets
$1.01B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$41.25M
Capital expenditures (TTM)
$674,000
R&D (TTM)
$123.98M
SG&A (TTM)
—
Stock compensation (TTM)
$36.89M
R&D / revenue
516.6%
Stock compensation / revenue
153.7%
Ownership (13F)
3 metrics13F filers
200
13F filer change QoQ
+8
Institutional ownership
100.2%
Short interest
3 metricsShort interest
10.8%
Latest settlement · 10.9 days to cover
Days to cover
10.9d
Short-squeeze score
85 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—